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A decapeptide highly homologous to the STa Escherichia coli heat-stable enterotoxin and to several other heat-stable 
enterotoxins was fused genetically to the amino-end of the B-subunit of cholera toxin (CTB) and the hybrid protein gene 
expressed from a tacP overexpression system. The STa-related decapeptide used, which was encoded by a synthetic oligo- 
deoxynucleotide, contained a single mutation which substituted a disulfide-linked cysteine by alanine. After its fusion 
to CTB the decapeptide was able to both react with and to give rise to anti-STa ntibodies. Expression of the decapeptide- 
CTB hybrid by non-toxigenic Vibrio cholerae resulted in its full secretion i to the extracellular milieu from where it could 
then be readily purified by single-step affinity chromatography using immobilized GM 1 ganglioside. Bacteria producing 
this non-toxic, immunogenic decapeptide-CTB toxoid might be useful for the development of oral vaccines against diar- 
rhea caused by E.coli and other bacteria producing immunologically related heat-stable enterotoxins, and as a source 
of immunoreagents for methods used to diagnose disease caused by these bacteria. 
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1. INTRODUCTION 
Infection by enterotoxigenic Escherichia coli 
(ETEC) is a major cause of diarrheal disease in in- 
fants and children in developing countries and in 
travellers visiting those places [1]. ETEC infections 
are also a common cause of disease in young 
domestic animals [2]. ETEC exerts its pathogenic 
effects by producing heat-labile or heat-stable 
enterotoxins (LTs and STs, respectively). 
There are two types of STs, STa and Stb, with 
different host specificity and protein structure [3]. 
Two kinds of STa molecules which vary only 
slightly have been identified; an STa subtype 
(STaI) produced by ETEC isolated from both 
humans and pigs which is 18 amino acids long and 
another (STaII) only isolated from strains infec- 
ting humans which is 19 amino acids in length 
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[4,5]. Both enterotoxins have six cysteines which 
are known to form intra-chain disulfide bridges 
[5]. The importance of the disulfide bridges for the 
toxicity of STa is a subject of great interest because 
of its bearance on the design of safe vaccines for 
protection against ETEC diarrhea. Recently amino 
acid substitutions at the genetic [6] or synthetic 
protein level [7] have provided useful clues on the 
role of the cysteine residues. 
Elaboration of protective antibodies against STa 
has the added requirement of having to make the 
protein, or its derivatives, immunogenic since the 
STa molecule itself is a very poor immunogen [8]. 
The problem of poor immunogenicity has been 
solved by coupling STa or its derivatives to larger 
carrier molecules o as to obtain effective antigens. 
Several proteins have been coupled chemically to 
STa for this purpose including BSA and the B- 
subunits of cholera toxin (CTB) and LT (LTB) 
[8,9]. The STa molecule has also been linked 
genetically to the A-subunit of LT (LTA) to give 
an LTA-STa hybrid protein which after associa- 
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t ion  wi th  unmodi f ied  LTB gave an LT ho lo tox in -  
l ike mo lecu le  expos ing  ef f ic ient ly  the STa ant igenic  
ep i topes  [10,11]. However ,  all STa-der ived  hybr id  
pro te ins  descr ibed  so far  bear  unmodi f ied  and  thus 
most  l ikely toxic  STa molecu les  and are there fore  
unsu i tab le  for  vacc inat ion  in humans .  In an e f fo r t  
to create  immunogen ic  hybr id  prote ins  lacking STa 
tox ic i ty  we have fused genet ica l ly  to the amino-end  
o f  CTB,  a decapept ide  whose  pr imary  sequence is 
ident ica l  to a reg ion in nat ive STa except  for  a 
mutat ion  that  replaces a cysteine res idue by 
a lan ine .  The  decapept ide -CTB hybr id  pro te in  so 
obta ined  had  no STa-assoc ia ted  toxic i ty  but  cou ld  
give rise to ant ibod ies  c ross - react ing  wi th  STa and 
was a lso ef f ic ient ly  recogn ized  by neutra l i z ing ant i -  
STa  ant ibod ies .  
2. MATERIALS  AND METHODS 
2.1. Bacterial strains, plasmids and DNA manipulations 
The E. coli strain HB101 was used as transistent host for 
plasmid isolations. The Vibrio cholerae strain JS1569 (J.S. and 
J.H., unpublished) is a rifampicin-resistant derivative of strain 
CVD103 [12]. The E. coli strain S17-1 [13] was used for con- 
jugal transfer of plasmids to strain JS1569. Plasmid pJS162 
(J.S. and J.H., unpublished) encodes resistance toampicillin. It 
is a derivative of the wide-host range plasmid pMMB68 [14] 
containing the CTB gene under the expression control of the 
IPTG-inducible tacP promoter. Plasmid pJS162 contains ingle 
SacI and XmaI restriction sites at the junction between the 
leader peptide and the mature CTB-encoding DNA sequences. 
Isolation of plasmid DNA by the alkali-lysis method including 
centrifugation i  CsC1/ethidium bromide gradients and DNA 
transformations were performed essentially as described by 
Maniatis et al. [15]. Conditions used for restriction and ligation 
of DNA were as recommended by the suppliers of the different 
enzymes (Boehringer Mannheim and New England Biolabs). 
The synthetic oligodeoxynucleotides encoding the STa-related 
decapeptide and adjacent amino acids (fig. 1) were purchased as 
complementary individual strands from Dr Lena Samuelsson, 
Department of Immunology, Biomedical Centre, Uppsala, 
Sweden. These strands were paired by mixing equimolar 
amounts of each strand and incubating the mixture overnight at 
room temperature. The resulting double-stranded oligo- 
nucleotide contained single-stranded extensions compatible 
with Sacl at the 5'-end and with Xmal  at the 3' -end and could 
therefore be ligated directly to SacI-Xmal-restricted pJS162. 
Ligation was performed by incubating a 10-fold molar excess of 
oligonucleotide to plasmid DNA overnight at 4°C with T4 DNA 
ligase. To the ligation mixture was then added in equimolar 
amounts with respect o the vector plasmid DNA a purified 
SacI-Xmal fragment from plasmid p J5162 containing the CTB 
gene, and the ligase reaction was then continued at 4°C for 
another 18 h. The ligated DNA was subsequently ransformed 
into competent E. coli HB101 cells with selection for ampicillin 
resistance (100/~g/ml). 
2.2. Growth o f  strains 
Strains were kept at -70°C in LB medium [15] containing 
15070 glycerol until used. Cultures were grown overnight or until 
they reached the desired absorbance (600 nm) with continuous 
shaking at 37°C (E. colt) or at 30°C (V. cholerae) in liquid LB 
containing ampicillin (100 ,ug/ml) and/or ifampicin (50/~g/ml) 
as appropriate. Induction by isopropyl-fl-D-thio-galacto- 
pyranoside (IPTG) of the expression of the tacP promoter was 
achieved either by addition of IPTG at the start of the culture 
(0.4 mM final concentration) or by first growing the strains to 
A6o0 0.5 in the absence of the inducer and then adding IPTG to 
the desired concentration and continuing the growth for 
another 4 h before harvesting. 
2.3. ELISA assays 
After growth of strains in liquid LB as described in section 
2.2, bacterial cells and culture supernatants were separated by 
centrifugation for 5 rain in a microcentrifuge (Eppendorf). Cell 
pellets were resuspended in cold phosphate-buffered saline (pH 
7.2) and disrupted by two 30-s sonic bursts (Branson sonifier). 
Detection of STa and CTB antigens in supernatants and cell 
sonicates was done by GMI-EL1SA as described [9,16] using 
monoclonal antibodies directed against native STa or CTB, 
respectively [9,16]. 
2.4. Immunoblots 
The decapeptide-CTB hybrid protein was purified from 
culture supernatants of V. cholerae strain JS1569 (pJS8) by 
single-step affinity chromatography on a lyso-GMl-spherosil ® 
column essentially as described [17]. 10 tzg of the purified pro- 
tein or reference CTB were subjected to electrophoresis on
13.5070 SDS-polyacrylamide gels in the absence of fl- 
mercaptoethanol, and the separated proteins were then elec- 
trotransferred to nitrocellulose essentially as described in the 
Bio-Rad Catalogue for the Protean and Trans-Blot Units (Bio- 
Rad, Richmond, CA). Afterwards the nitrocellulose membrane 
was incubated with mouse anti-STa or anti-CTB monoclonal 
antibodies followed by incubation with anti-mouse IgG coupled 
to peroxidase (Jackson Biologicals). Immunoreactive protein 
bands were finally developed with the aid of a cbloronaphthol 
substrate. 
2.5. Infant mouse toxicity assay 
The infant mouse toxicity assay [18] was used to assess any 
STa-related toxic activity of the decapeptide-CTB hybrid pro- 
tein. Purified hybrid protein, or for comparison purified native 
STa [7,9], was injected intragastrically into 2-3-day-old mice 
who 3-4 h after injection were killed and examined for in- 
creased gut-to-body weight ratio as described [18]. 
2.6. Immunizations and antibody assay 
Adult rabbits were immunized biweekly by two subcutaneous 
injections with 150/~g of purified decapeptide-CTB (equivalent 
to 12 tzg of decapeptide) followed by a third injection with 
1.2 mg hybrid protein (equivalent to 96/~g of decapeptide). In 
the first immunization the antigen was given together with com- 
plete Freunds adjuvant and in the subsequent ones with in- 
complete adjuvant. 
Anti-STa reactive antibody titers in rabbit antisera were 
determined using a microtiter ELISA method [19] with plastic- 
attached synthetic STa as solid-phase antigen. 
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3. RESULTS 
3.1. Gene fusion o f  the STa-related ecapeptide to 
CTB 
Plasmid pJS162 which contains ingle SacI and 
XmaI  restriction sites at the junct ion between the 
leader peptide and mature CTB was digested with 
the corresponding enzymes and then ligated to the 
synthetic ol igodeoxynucleotide encoding the STa- 
homologous decapeptide (fig.l) via the SacI and 
XrnaI compatible nds. This resulted in plasmid 
pJS8 possessing a hybrid gene under the control of 
the tacP promoter that encodes a fusion protein in 
which the STa-related decapeptide, f lanked by a 
few extra amino acids, is covalently linked to the 
amino-end of mature CTB (fig.l). 
3.2. Expression o f  the STa-related decapeptide- 
CTB hybrid and its secretion by V. cholerae 
The STa-related ecapeptide-CTB hybrid encod- 
ed by pJS8 was initially identified in transformed 
E. coli 101 grown in the presence of IPTG as 
described above. Plasmid pJS8 was subsequently 
transferred by conjugat ion to V. cholerae JS1569 
using a helper E. coli strain (S17-1) as an in- 
termediate host. The expression of the hybrid gene 
in V. cholerae JS1569 was then studied after 
culture with addit ion of different concentrations 
of IPTG during the logarithmic phase of growth 
and the cellular localization of the decapeptide- 
CTB protein was determined as well. The results in 
fig.2 show that the hybrid protein was produced in 
a clearly IPTG-dependent  manner  and was fully 
secreted to the extracellular milieu. This location 
of the decapeptide-CTB facilitated its purif ication 
by aff inity chromatography. 
The decapeptide-CTB protein exhibited no toxic 
activity tested in amounts of up to 10/~g in the in- 
fant mouse assay. Concurrent ly tested purified 
native STa gave positive infant mouse tests in 
amounts  down to 1 ng, i.e. a 10000-fold lower 
dose. 
3.3. Immunogenicity o f  the STa-related 
decapeptide-CTB 
When the purified protein was used to immunize 
rabbits it gave rise to antibodies which cross- 
reacted with native STa. The anti-STa titer deter- 
mined by EL ISA using synthetic, plastic-coated 
STa as a solid phase antigen rose from an undetec- 
+ + + * . * * * * 
Arg  I le His Cys A la  Glu Leu Cys Cys 
agct AGA ATT  CAC TGC GCT GAA TTG TGT TGT 
. . . . + + + + + + 
Asn Pro  A la  Cys Pro  G ly  Tyr  A la  His  Gly  
AAT  CCT GCA TGC Ccc  ggg  tat  gca cat  gga 
Fig.1. Fusion of STa-related decapeptide to CTB. A synthetic 
oligodeoxynucleotide (indicated by bold capital etters) with 
single-stranded extensions compatible to Sacl and XmaI 
restriction ends was inserted into the DNA region encoding the 
amino-end of the CTB in plasmid pJS162. Insertion of the 
synthetic oligonucleotide was performed so as to maintain the 
original reading frame in the CTB gene and resulted in a hybrid 
gene encoding a fusion protein containing a peptide xtension 
comprising the STa-related peptide (indicated by asterisks) at 
the amino-end of CTB (first amino acid indicated by the + 1 
number). The amino acids signaled by (+) are amino acids 
encoded by the indicated oligonucleotide which are not 
considered to form part of the STa-related ecapeptide. 
Upstream of the first amino acid (Arg), there is a leader peptide 
for CTB originating from a gene encoding LTB, a ribosome 
binding site (S/D) and the tacP promoter for expression f the 
hybrid gene (J.S. and J.H., unpublished). 
Hybrid protein 
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Fig.2. Induction of STa-related ecapeptide-CTB hybrid gene 
expression by IPTG in V. cholerae JBK70 harbouring plasmid 
pJS8. Cells were grown in liquid medium to A6oo 0,5 in the 
absence of inducer and then IPTG was added at the indicated 
concentrations and cultivation of bacteria continued for 
another 4h before bacterial cells and culture supernatants were 
harvested as described in the text. Levels of hybrid protein 
(ordinate) were determined by GM1-ELISA using a specific 
monoclonal anti-STa antibody, ST 1:3. Purified STa-related 
decapeptide-CTB hybrid protein was used as a reference. Stars 
denote concentrations of hybrid protein supernatants and open 
squares cell-associated concentrations determined after 
disruption of the cells by ultrasonication. 
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table level in preimmunization serum to a titer of 
1:2000 after three subcutaneous immunizations. 
This titer rise compared favourably with the anti- 
ST response attained in rabbits by immunization 
with a chemically derived hybrid protein carrying 
native STa [4]. 
3.4. Immunoblot analyses of the STa-related 
decapeptide-CTB 
Purified STa-related ecapeptide-CTB and con- 
trol CTB were subjected to SDS-polyacrylamide 
electrophoresis in the absence of B-mercapto- 
ethanol and the separated proteins reacted in 
parallel in immunoblot assays with anti-CTB and 
anti-STa. Protein samples were either boiled or left 
at room temperature in sample buffer before elec- 
trophoresis to facilitate analyses of the im- 
munoreactive proteins in their pentameric and 
monomeric forms [11]. Reaction with anti-CTB 
revealed bands at the positions expected for the 
pentameric forms of the control CTB (fig.3, lane 
a) or STa-related ecapeptide-CTB hybrid protein 
(fig.3, lane c). Incubation with anti-STa of the 
respective boiled and unboiled samples developed 
- -  
a b c d e f g h 
Fig.3. lmmunoblotting analysis of STa-related ecapeptide- 
CTB hybrid protein after SDS-polyacrylamide gel 
electrophoresis followed by electrotransfer of separated 
proteins onto nitrocellulose paper. Lanes show reaction 
patterns of unboiled purified 569B CTB (a), boiled CTB (b), 
unboiled STa-related ecapeptide-CTB (c) and boiled STa- 
related decapeptide-CTB (d) after development with anti- 
cholera toxin monoclonal ntibody Wi7 : 5. Lanes e-b show the 
reaction patterns obtained for the same proteins after 
development with anti-STa monoclonal ntibody ST 1:3. 
Arrows refer to the migration positions of reference proteins 
with known molecular masses (indicated as kDa) run on the 
same gel. 
bands corresponding to the pentameric and 
monomeric forms of the decapeptide-CTB protein 
(fig.3, lanes g and h) and failed to react with either 
the pentameric or monomeric forms of the control 
CTB (fig.3, lanes e and f). The monomeric form of 
CTB did not react with anti-CTB (fig.3, lane b) 
whereas a minor reaction of the monomeric form 
of the decapeptide-CTB with this antibody was 
observed (fig.3, lane d). 
4. DISCUSSION 
The STa heat-stable nterotoxin of E. coli has 
six cysteine residues in its primary structure which 
are known to form three intra-chain disulfide 
bridges [5]. The cysteine residues are contained 
within a 15 amino acid stretch of the protein and 
this region is not only identical between the two 
different variants of STa molecules known (STa I 
and STa II) but it also shares extensive homology 
with the heat-stable nterotoxins from non-01 V. 
cholerae and Yersinia enterocolitica [20,21]. The 
multiple disulfide bridges in STa have been im- 
plicated in its toxicity [22] and they have thus 
become targets for manipulations with the aim to 
obtain safe vaccine candidates. 
Amino acid replacements on STa using site- 
specific mutagenesis have provided important 
clues on the role of individual cysteines on the tox- 
ic properties of STa [6]. Similarly, chemical syn- 
thesis of cysteine-substituted non-toxic STa 
analogues able to bind anti-STa antibodies has 
recently furnished extra information on the 
significance of the disulfide bridges on some im- 
munorelevant epitopes [7]. Substitutions or sup- 
pressions of the cysteine residues to eliminate the 
toxicity of STa have probably got to be done 
carefully so as not to alter the overall conforma- 
tion of the protein risking to eliminate its protec- 
tive epitopes. Here we have fused a synthetic DNA 
sequence ncoding a decapeptide which is identical 
to a region contained in STa except for a replace- 
ment of one of the 5 cysteines in this region for an 
alanine residue. The decapeptide was fused to the 
CTB gene in plasmid pJS162, which is expressed 
from a recently developed tacP-directed overex- 
pression system (J.S. and J .H.,  unpublished). The 
gene fusion resulted in the synthesis of a hybrid 
protein where the decapeptide was joined to the 
amino-end of CTB. The sequence of the decapep- 
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tide fused was chosen based on our recent f inding 
of  the ant i -STa ant ibody-b inding capacity of  a 
non-toxic  synthetic nonadecapept ide peptide 
which contains this amino acid replacement [7]. 
The sequence fused here is, however, shorter and 
comprises only 10 amino acids including four cys- 
teines. 
The decapept ide-CTB protein exhibited no tox- 
icity in the infant mouse intragastr ic assay nor did 
the synthetic nonadecapept ide containing this se- 
quence [7]. Furthermore,  the STa-related 
decapept ide-CTB hybrid protein was able to effi- 
ciently bind ant i -STa ant ibodies both in 
GMI -EL ISA  and in immunob lo t  analyses. The 
hybr id  protein exhibited, in addit ion,  a number of  
attr ibutes characterist ic of  the CTB moiety such as 
the abi l i ty to pentamerize,  to bind to the GM1 
receptor  and to be secreted by V. cholerae [23]. 
The latter two propert ies made possible purif ica- 
t ion of  the decapept ide-CTB from V. cholerae 
culture supernatants by a single-step receptor- 
specific af f in i ty chromatography  procedure 
developed for the pur i f icat ion of  CTB [17]. When 
the pur i f ied protein was used to immunize rabbits 
it gave rise to ant ibodies which cross-reacted with 
native STa. The ant i -STa titers obtained compared 
favourab ly  with the ant i -STa titers attained using 
a chemical ly derived hybr id protein carrying STa 
[24]. This f inding together with the lack of  toxicity 
now warrants studies on the protect ive im- 
munogenic i ty  of  the STa-related ecapept ide-CTB 
prote in against STa-associated ETEC diarrhea in 
exper imental  nimals and,  if promis ing results are 
obta ined,  also in humans.  As ment ioned above the 
decapept ide-CTB protein retained full capacity to 
bind to GM1 while reacting strongly with ant i -STa 
ant ibodies.  These propert ies al low the use of  the 
hybr id protein as an immunoreagent  for detection 
o f  STa by GMl - inh ib i t ion  EL ISA  [23]. Indeed, 
evidence is now avai lable indicat ing that not only 
the decapept ide-CTB hybr id can be used as a 
reagent to detect STa in culture supernatants of  
cl inical isolates of  enterotoxigenic E. co# but that 
this protein is superior to other genetical ly obtain-  
ed ST-LT hybrids [10,11] in this test (J.S. and 
A .M.S . ,  unpubl ished).  
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